Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause

VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes

The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities

Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI

Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC

Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial

PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients

OneSource bags SFDA nod for generic Ozempic in Saudi Arabia

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

Time Medical India unveils next-generation MRI platforms at IRIA 2026

The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets

Cirena launches to revolutionize long RNA production for CRISPR & gene editing

As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects